Comparison of ticagrelor with clopidogrel on quality of life in patients with acute coronary syndrome

BACKGROUND: Ticagrelor has a Class I recommendation for use following percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS). However, ticagrelor needs to be taken twice a day, as compared to clopidogrel. Its adverse effects, such as dyspnea or bleeding, are known to be more commo...

Descripción completa

Detalles Bibliográficos
Autores principales: Moon, Hyeyeon, Jo, Yoon-Sung, Kim, Soo-Jin, Jo, Sua, Park, Kyungil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520288/
https://www.ncbi.nlm.nih.gov/pubmed/34656119
http://dx.doi.org/10.1186/s12955-021-01875-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520288/
https://www.ncbi.nlm.nih.gov/pubmed/34656119
http://dx.doi.org/10.1186/s12955-021-01875-w

Ejemplares similares